Tekrardan Hoşgeldiniz
Cointime'ın Hizmet Şartları'ini kabul etmek ve Cointime'ın Gizlilik Politikası'inin sizin için geçerli olduğunu onaylamak için "Giriş "a tıklayın.
Cointime’a Katıl
Çoktan Hesabın Var mı?
Cointime'ın <a class="underline" href="#term-of-service">Hizmet Şartları</a>'ini kabul etmek ve Cointime'ın a class="underline" href="#privacy-policy">Gizlilik Politikası</a>'inin sizin için geçerli olduğunu onaylamak için "page.Sign up "a tıklayın.
Giriş Yap
Kayıt Ol
Posta kutunuz
Gelen kutunuzu kontrol edin
Giriş yapmak için emaildeki bağlantıya tıklayın.
Kayıt olmak için emaildeki bağlantıya tıklayın.
CinCor Pharma
company
About
CinCor is a clinical-stage biopharmaceutical company that develops treatments for cardiovascular diseases.
- 11 - 50
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $143M
- Industries
- Biotechnology,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2018
- Number Of Employee
- 11 - 50
- Operating Status
- Active
CinCor is a clinical-stage biopharmaceutical company with a mission to advance promising clinical candidates toward marketing approval. CinCor’s focus is on cardiovascular, metabolic and kidney diseases. CinCor’s lead program is CIN-107, a novel aldosterone synthase inhibitor.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$143M
CinCor Pharma has raised a total of
$143M
in funding over 2 rounds. Their latest funding was raised on
Oct 12, 2021 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 12, 2021 | Series B | $143M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
CinCor Pharma is funded by 1 investors.
Lilly Asia Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Lilly Asia Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
